Eton Pharmaceuticals to pay Aquestive $10 million upfront under license agreement
AQST•Eton Pharmaceuticals will pay Aquestive a $10 million upfront license fee, up to $47.5 million in milestone payments and mid-teens royalties on Libervant sales under a supply agreement with an initial 20-year term.
1. Agreement terms
Eton Pharmaceuticals will pay Aquestive a $10 million upfront license fee and up to $47.5 million in milestone payments. The agreement provides for royalties at a mid-teens percentage rate on Libervant sales and has an initial term of 20 years.
